This presentation takes a look at the contents of the long awaited GAMP®5 Version 2 release to examine what has truly changed since the Version 1 release, with special focus on what might impact regulated laboratories in the Pharma, BioPharma, and Biotech industries.
Viewers should learn what the major changes are for Version 2 and how they might impact their current regulated lab operations so they can make pro-active updates to their current compliance related procedures and policies.
What you need to know:
Duration: Approximately 1 hour
Global Sr. Product Manager, Agilent Technologies, Inc.
Michael has 25 years of experience in regulated environments in the Pharmaceutical and Bio-Tech industries. Half of Michael's career has been spent on the customer side of the industry in both IT and Laboratory positions; supporting, qualifying, and validating regulated computerized systems and instruments. The other half has been spent providing consultative compliance services from the vendor side of the industry. His experience includes validating laboratory informatics systems, as well as instrument qualification, preventive maintenance, and relocation services.
Michael has held various IT and Lab positions at MannKind Corporation and Purdue Pharma, as well as consulted for Pfizer, JnJ, TEVA, and Merck. Michael has also held various positions at Waters Corporation, PerkinElmer OneSource, and Agilent Technologies. He currently serves as the Senior Product Manager of Compliance Consulting services on the global Marketing team at Agilent Technologies. Michael holds a B.S. in Biology, with minors in Chemistry and Environmental Science.